RxDoctor Payments Data

Nilanthi Gunawardane, MD

Dermatology · Orange, CANPI 1124351051

Payments from drug & device makers

$3,092in general payments, 2019–2025

Across 121 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$781
  • Sanofi$603
  • Johnson & Johnson$528
  • Novartis$234
  • Aurinia Pharma U.S., Inc.$205
  • Mallinckrodt Hospital Products Inc.$159
  • plus $583 from 11 others

What the payments were for

  • Food & beverage$3,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,092 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$74,870
Medicare patients
220
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$54,250
OpzeluraRuxolitinib Phosphate17$33,178
Clobetasol Propionate173$5,967
Fluorouracil103$5,802
Fluocinonide68$2,161
Clindamycin Phosphate66$1,984
Doxycycline Hyclate85$1,933
Tacrolimus24$1,754
Betamethasone Dipropionate47$1,726
Ketoconazole95$1,330
Tretinoin15$1,188
Triamcinolone Acetonide104$906
Calcipotriene15$891
Metronidazole21$878
Ciclopirox25$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$73$54,25012 claims
Incyte CorporationOpzelura$119$33,17817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,875 dermatology providers in California.

Other dermatology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →